Abstract:Despite advancements in standard treatments, the prognosis of Glioblastoma (GBM) remains poor, prompting research for novel therapies. Immunotherapy is a promising treatment option for GBM, and many immunotherapeutic agents are currently under investigation. Chimeric antigen receptor (CAR) T cells are rapidly evolving in immunotherapy of GBM with many clinical trials showing efficacy of CAR T cells exerting anti-tumor activity following recognition of tumor-associated antigens (TAAs). Exhaustion in CAR T cells can reduce their capacity for long-term persistence and anti-tumor action. Local immunotherapy, which targets the tumor microenvironment and creates a more hospitable immunological environment for CAR T cells, has the potential to reduce CAR T cell exhaustion and increase immunity. Tertiary lymphoid structures (TLS) are ectopic lymphoid-like formations that can develop within the tumor microenvironment or in other non-lymphoid tissues. As a comprehensive local immunotherapy tool, the incorporation of TLS into an implanted biodegradable scaffold has amazing immunotherapeutic potential. The immune response to GBM can be improved even further by strategically inserting a stimulator of interferon genes (STING) agonist into the scaffold. Additionally, the scaffold's addition of glioma stem cells (GSC), which immunotherapeutic approaches may use to target, enhances the removal of cancer cells from their source. Furthermore, it has been demonstrated that GSCs have an impact on TLS formation, which helps to create a favorable tumor microenvironment. Herein, we overview local delivery of a highly specific tandem AND-gate CAR T cell along with above mentioned components. A multifaceted approach that successfully engages the immune system to mount an efficient targeted immune response against GBM is provided by the integration of CAR T cells, TLS, STING agonists, and GSCs within an implantable biodegradable scaffold. This approach offers a promising therapeutic approach for patients with GBM.

Advances in local therapy for glioblastoma — taking the fight to the tumour

Local therapy in glioma: An evolving paradigm from history to horizons (Review)

Local immunotherapy of glioblastoma: A comprehensive review of the concept

Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials

Clinical and translational advances in primary brain tumor therapy with a focus on glioblastoma-A comprehensive review of the literature

Stemness, invasion, and immunosuppression modulation in recurrent glioblastoma using nanotherapy

Glioblastoma Therapy: Past, Present and Future

Advancements in surgical management of glioblastoma: current trends and promising future directions

Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme

Advancements in Glioblastoma Management: A Comprehensive Review of Therapeutic Strategies and Future Directions

Innv-18. Focus On Current And Emerging Treatment Options For Glioma: A Comprehensive Review

Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins

Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment

Advances in immunotherapeutic research for glioma therapy

Pharmacological strategies for improving the prognosis of glioblastoma

Current Advances in Immunotherapy for Glioblastoma

Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies

Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms

Clinical immunotherapy in glioma: current concepts, challenges, and future perspectives